Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Inclusion Criteria:

- Pathologically confirmed T or NK cell lymphoma at the enrolling institution. For CTCL,
patients with stage IB disease or greater are eligible.

- Relapse or refractory disease after at least 1 systemic therapy except for T-PLL where
untreated patients may be allowed after discussion with P.I.

- Age ≥ 18

- ECOG ≤ 2

- Measurable disease defined by:

- Lugano Classification for systemic lymphoma or

- Atypical and or malignant lymphocytes quantifiable by flow cytometry or
morphology in blood or bone marrow or

- mSWAT > 0 or Sezary count ≥ 1000 cells/μL for CTCL

- Previous systemic anti-cancer therapy for T-cell lymphoma must have been discontinued
at least 2 weeks prior to treatment.

- Glucocorticoids aimed at controlling lymphoma-related symptoms are allowed as
long as they are tapered down to 20mg or less by the time of ruxolitiib
initiation

- Topical steroids for CTCL are permitted

- See section 6.2 Subject Exclusion Criteria for guideline regarding adjuvant and
maintenance therapy for prior malignancy

- Patients must meet the following lab criteria:

- ANC ≥ 1.0/mm^3, ANC >/= 0.5/mm^3 (if patient has baseline neutropenia due to
lymphoma), platelets ≥ 100 x 10^9/L or ≥ 50 x 10^9/L (if related to lymphoma),
Hgb ≥ 8g/dL

- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or; ≤ 3 x ULN if documented
hepatic involvement with lymphoma, or ≤ 5 x ULN if history of Gilbert's ; AST and
ALT ≤ 3 x ULN; ≤ 5 x ULN if due to lymphoma involvement

- Creatinine clearance ≥ 30 mL/min; creatinine clearance of 15-29 mL/min will be
allowed as long as baseline platelets are ≥ 150 x 10^9/L

- For patients with positive hepatitis B core antibody or surface antigen, hepatitis B
PCR must be negative and prophylaxis with entecavir or equivalent is required.

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

- Uncontrolled concurrent illness including, but not limited to, ongoing or active
infection, uncontrolled diabetes, clinically significant pneumonitis, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit compliance with study requirements.

- ECOG performance status >2

- Prior therapy with ruxolitinib

- Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma)

- Patients with more than one type of lymphoma may be enrolled after discussion
with the MSK Principal Investigator

- Adjuvant or maintenance therapy to reduce the risk of recurrence of other
malignancy (other than T-cell lymphoma) is permissible after discussion with the
MSK principal Investigator

- Known history of testing positive for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS) within 12 months prior to initiating study
treatment.

- Women of reproductive potential† must have a negative Serum ß human chorionic
gonadotropin (ß-HCG) pregnancy test.

- A female of reproductive potential is a sexually mature female who: has not
undergone a hysterectomy or bilateral oophorectomy; or has not been naturally
postmenopausal for at least 24 consecutive months (i.e. has had menses at any
time in the preceding 24 consecutive months).